Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03407378 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate a New Treatment in Patients With Parkinson's Disease

A Phase 1 study of Parkinson Disease, sponsored by Tools4Patient.

Completed
Registry status
Phase 1
Development phase
110
Enrollment target
10
Study locations

NCT03407378: Completed Phase 1 study of Parkinson Disease, sponsored by Tools4Patient.

NCT03407378 is a Phase 1 study of Parkinson Disease that has completed, run by Tools4Patient. The registered enrollment target is 110 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03407378, a Phase 1 study of Parkinson Disease, has completed, sponsored by Tools4Patient.

COMPLETED
Registry status
Phase 1
Development phase
110 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this clinical trial conducted in patients with Parkinson's Disease is to study the relationship between patient individual profile and their response to IPT803 Adjunct Treatment (treatment response being characterized by movements improvement).

Primary Outcome

Part III of the MDS-UPDRS (or motor examination) assesses the motor abilities in PD patients at the time of the visit. This part measures 18 motor examinations such as speech, facial expression, tremor, rigidity, finger tapping, pronation-supination movements of hands, leg agility, arising from chair, gait. The qualified rater must score 34 items from 0 to 4, where 0 indicates a normal situation and 4 indicates that PD interferes severely in carrying out the task. The total score, being the sum

Conditions Studied

Parkinson Disease

Interventions

  • OTHER Questionnaires
  • DRUG IPT803
  • GENETIC Optional pharmacogenetic assessment
  • OTHER Optional Blood-Oxygen-level Dependent functionalMRI
  • OTHER Motor Assessments before taking regular PD treatment

Study Locations (10)

Other

  • CHU Liege - Liège University - Liège
  • CHU Grenoble - Grenoble
  • CHU Poitiers - Poitiers
  • CHU Rennes - Hopital Pontchaillou - Rennes
  • CHU Purpan - Hopital Pierre Paul Riquet - Toulouse

Colorado

  • University of Colorado School of Medicine - Aurora

Florida

  • University of Florida - Gainesville

Illinois

  • Northwestern - Chicago

Michigan

  • Henry Ford - West Bloomfield

New York

  • Columbia - New York

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2018-06-26
Est. Completion 2020-03-31
Phase Phase 1
Tools4Patient

2 total trials

What the finished NCT03407378 record still lists

NCT03407378 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 5 interventions - of which Questionnaires is the first listed.

NCT03407378 lists 10 locations in 6 states (Other, Colorado, Florida).

Frequently Asked Questions

What is clinical trial NCT03407378 about?

NCT03407378 is a clinical study titled "A Study to Investigate a New Treatment in Patients With Parkinson's Disease". The purpose of this clinical trial conducted in patients with Parkinson's Disease is to study the relationship between patient individual profile and their response to IPT803 Adjunct Treatment (treatment response being characterized by movements improvement).

What is the current status of trial NCT03407378?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2018-06-26. Estimated completion is 2020-03-31.

What conditions does trial NCT03407378 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT03407378?

The interventions under investigation include: Questionnaires (OTHER), IPT803 (DRUG), Optional pharmacogenetic assessment (GENETIC), Optional Blood-Oxygen-level Dependent functionalMRI (OTHER), Motor Assessments before taking regular PD treatment (OTHER).

Who is sponsoring clinical trial NCT03407378?

This trial is sponsored by Tools4Patient, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03407378 being conducted?

This trial has 10 study locations across Colorado, Florida, Illinois, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03407378's enrollment target sits among peer trials

110 82nd of 297 higher than 216 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT02411773 · 110 participants · Phase 1

    Sympatholysis in Chronic Kidney Disease

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03407378, the US trial registry maintained by the National Library of Medicine. NCT03407378 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.